15.76 USD
+0.01 (+0.06%)
We assign a fundamental rating of 2 out of 10 to BNR. BNR was compared to 529 industry peers in the Biotechnology industry. Both the profitability and financial health of BNR have multiple concerns. BNR is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year BNR has reported negative net income.
BNR had a negative operating cash flow in the past year.
In the past 5 years BNR always reported negative net income.
In the past 5 years BNR always reported negative operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of -14.93%, BNR is in the better half of the industry, outperforming 79.96% of the companies in the same industry.
With an excellent Return On Equity value of -22.06%, BNR belongs to the best of the industry, outperforming 81.66% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -14.93% | ||
| ROE | -22.06% | ||
| ROIC | N/A |
ROA(3y)-54.4%
ROA(5y)-43.17%
ROE(3y)-76.2%
ROE(5y)-58.25%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
BNR has a better Gross Margin (73.02%) than 82.61% of its industry peers.
In the last couple of years the Gross Margin of BNR has remained more or less at the same level.
BNR does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 73.02% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.68%
GM growth 5Y-0.38%
2. Health
2.1 Basic Checks
BNR does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for BNR remains at a similar level compared to 1 year ago.
Compared to 5 years ago, BNR has more shares outstanding
There is no outstanding debt for BNR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
Based on the Altman-Z score of -3.66, we must say that BNR is in the distress zone and has some risk of bankruptcy.
BNR has a Altman-Z score (-3.66) which is comparable to the rest of the industry.
A Debt/Equity ratio of 0.00 indicates that BNR is not too dependend on debt financing.
With a Debt to Equity ratio value of 0.00, BNR perfoms like the industry average, outperforming 47.26% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -3.66 |
ROIC/WACCN/A
WACC7.54%
2.3 Liquidity
BNR has a Current Ratio of 3.14. This indicates that BNR is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 3.14, BNR is doing worse than 63.52% of the companies in the same industry.
BNR has a Quick Ratio of 2.91. This indicates that BNR is financially healthy and has no problem in meeting its short term obligations.
BNR's Quick ratio of 2.91 is on the low side compared to the rest of the industry. BNR is outperformed by 64.08% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.14 | ||
| Quick Ratio | 2.91 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 93.72% over the past year.
Looking at the last year, BNR shows a small growth in Revenue. The Revenue has grown by 5.56% in the last year.
BNR shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 6.21% yearly.
EPS 1Y (TTM)93.72%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%55.1%
Revenue 1Y (TTM)5.56%
Revenue growth 3Y0.52%
Revenue growth 5Y6.21%
Sales Q2Q%2.31%
3.2 Future
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
Based on estimates for the next years, BNR will show a quite strong growth in Revenue. The Revenue will grow by 15.51% on average per year.
EPS Next Y-277.41%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year48.35%
Revenue Next 2Y17.89%
Revenue Next 3Y16.85%
Revenue Next 5Y15.51%
3.3 Evolution
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for BNR. In the last year negative earnings were reported.
Also next year BNR is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A
5. Dividend
5.1 Amount
No dividends for BNR!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
NASDAQ:BNR (12/15/2025, 8:09:00 PM)
15.76
+0.01 (+0.06%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners21.19%
Inst Owner Change-17.12%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap161.68M
Revenue(TTM)539.27M
Net Income(TTM)-121.25M
Analysts80
Price TargetN/A
Short Float %0.51%
Short Ratio0.9
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 2.12 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 2.08 | ||
| P/tB | 2.08 | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.72
EYN/A
EPS(NY)-1.02
Fwd EYN/A
FCF(TTM)-0.45
FCFYN/A
OCF(TTM)-0.45
OCFYN/A
SpS7.45
BVpS7.59
TBVpS7.59
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -14.93% | ||
| ROE | -22.06% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 73.02% | ||
| FCFM | N/A |
ROA(3y)-54.4%
ROA(5y)-43.17%
ROE(3y)-76.2%
ROE(5y)-58.25%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.68%
GM growth 5Y-0.38%
F-Score5
Asset Turnover0.66
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.14 | ||
| Quick Ratio | 2.91 | ||
| Altman-Z | -3.66 |
F-Score5
WACC7.54%
ROIC/WACCN/A
Cap/Depr(3y)26.43%
Cap/Depr(5y)152.99%
Cap/Sales(3y)5.44%
Cap/Sales(5y)15.37%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)93.72%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%55.1%
EPS Next Y-277.41%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)5.56%
Revenue growth 3Y0.52%
Revenue growth 5Y6.21%
Sales Q2Q%2.31%
Revenue Next Year48.35%
Revenue Next 2Y17.89%
Revenue Next 3Y16.85%
Revenue Next 5Y15.51%
EBIT growth 1Y79.72%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y89.46%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y89.46%
OCF growth 3YN/A
OCF growth 5YN/A
BURNING ROCK BIOTECH LTD-ADR / BNR FAQ
Can you provide the ChartMill fundamental rating for BURNING ROCK BIOTECH LTD-ADR?
ChartMill assigns a fundamental rating of 2 / 10 to BNR.
What is the valuation status of BURNING ROCK BIOTECH LTD-ADR (BNR) stock?
ChartMill assigns a valuation rating of 0 / 10 to BURNING ROCK BIOTECH LTD-ADR (BNR). This can be considered as Overvalued.
What is the profitability of BNR stock?
BURNING ROCK BIOTECH LTD-ADR (BNR) has a profitability rating of 2 / 10.
Can you provide the expected EPS growth for BNR stock?
The Earnings per Share (EPS) of BURNING ROCK BIOTECH LTD-ADR (BNR) is expected to decline by -277.41% in the next year.